Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Status: Recruiting
Location: See location...
Intervention Type: Drug, Radiation
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined with Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Participants aged 18 to 75 years, regardless of gender;
• ECOG Performance Status (PS) score of 0-1;
• Expected survival duration of no less than 8 weeks;
• Histologically or cytologically confirmed extensive small cell lung cancer (according to the VALG staging system);
• Subjects must not have received systemic therapy or radical radiotherapy for extensive SCLC prior to enrollment.
Locations
Other Locations
China
West China Hospital of Sichuan University
RECRUITING
Sichuan
Contact Information
Primary
You Lu
radyoulu@hotmail.com
02885424619
Backup
Zhuoran Yao, M.D.
yaozhuoran@outlook.com
Time Frame
Start Date: 2024-12-23
Estimated Completion Date: 2028-12
Participants
Target number of participants: 202
Treatments
Experimental: Group A
Adebrelimab combined with chemotherapy synchronous LDRT
Active_comparator: Group B
Adebrelimab combined with chemotherapy
Related Therapeutic Areas
Sponsors
Leads: Sichuan University
Collaborators: Shanghai Shengdi Pharmaceutical Co., Ltd